Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer

International Journal of Cancer

Volumn 109, Issue 1, 2004, Pages 144-148

  Gruber, Guenther ^a,c   Ciriolo, Michele ^a   Altermatt, Hans Joerg ^b   Aebi, Stefan ^a   Berclaz, Gilles ^a   Greiner, Richard H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Pathology Langgasse   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Combined treatment; Dermal lymphatic invasion; Occult inflammatory carcinoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LINEAR ACCELERATOR; LYMPH NODE METASTASIS; LYMPH VESSEL; MASTECTOMY; METASTASIS; MULTIVARIATE ANALYSIS; OCCULT CANCER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SKIN TUMOR; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR CELL; TUMOR EMBOLISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SKIN NEOPLASMS; TIME FACTORS;

EID: 0742287875     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11684     Document Type: Article

References (14)

1. Bryant T. Diseases of the breast. Wood's Med Surg Monogr 1889;4:35-322.
2. Meyer AC, Dockerty MB, Harrington SW. Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1948;87:417-24.
3. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer 1978;41:1595-605.
4. Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, Martin PM, Serment H, Piana L. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer 1995;62:382-5.
5. Wittekind C, Wagner G, eds. UICC: TNM-Klassifikation maligner Tumoren, 5. Heidelberg: Springer, 1997.
6. Saltzstein SL. Clinically occult inflammatory carcinoma of the breast. Cancer 1974;34:382-8.
7. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985;4:291-7.
8. Kuske RR. Diagnosis and management of inflammatory breast cancer. Semin Radiat Oncol 1994;4:270-82.
9. Amparo RS, Angel CD, Ana LH, Antonio LC, Vicente MS, Carlos FM, Vicente GP. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat 2000;64:269-73.
10. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena MP. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Cancer 1989;64:1922-7.
11. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990;5:131-5.
12. Riou G, Le M, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 1993;85:1765-7.
13. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999;90:977-81.
14. Fields JN, Kuske RR, Perez CA, Fineberg BB, Bartlett N. Prognostic factors in inflammatory breast cancer. Cancer 1989;63:1225-32.